Melane Sampson, Author at BioTuesdays

Developments

Lancet Rheumatology publishes Eupraxia’s Phase 2b data on EP-104IAR in knee OA

Eupraxia Pharmaceuticals (NASDAQ:EPRX; TSX:EPRX) has announced that the top-tier, peer-reviewed journal, Lancet Rheumatology, has published Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment...

October 15, 2024

Executive Moves

Lake Street Captial Markets names Alex Nowak as director investment banking

Alex Nowak has joined Lake Street Capital Markets’ growing banking team as director of the healthcare investment banking practice. In his new role, Mr. Nowak will focus on expanding client relationships and supporting...

October 15, 2024

Feature

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

Closely-held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...

October 15, 2024

Developments

Turnstone restructures to focus resources on advancing Phase 1 study

Turnstone Biologics (NASDAQ:TSBX) has announced restructuring initiatives that include the strategic prioritization of its pipeline, a 60% workforce reduction, and changes to its leadership team, aimed at focusing...

October 11, 2024

Developments

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Palisade Bio (NASDAQ:PALI) has announced that it has received a No Objection Letter from Health Canada for its Phase 1 clinical trial of PALI-2108 for the treatment of ulcerative colitis (UC). The orally-administered...

October 10, 2024

Developments

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to...

October 10, 2024

Developments

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF) has announced the completion of patient enrollment in a pivotal clinical study evaluating its next-generation Perimeter B-Series OCT system, which combines proprietary...

October 3, 2024

Executive Moves

Eupraxia expands Amanda Malone’s leadership role and names Rahul Sarugaser as EVP, corporate development

Eupraxia Pharmaceuticals (TSX:EPRX; NASDAQ:EPRX) has announced the appointments of Amanda Malone as chief operating and scientific officer and Rahul Sarugaser as executive vice president of corporate development. In her...

October 3, 2024

Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

Developments

Valerio acquires oncology biotech, Emglev

Valerio Therapeutics (Euronext Paris:ALVIO) has announced the acquisition of closely-held Emglev Therapeutics, a single-domain antibody-based therapeutic company and spinoff of Institut Curie, a leading cancer center in...

September 30, 2024

Author - Melane Sampson

Lancet Rheumatology publishes Eupraxia’s Phase 2b data on EP-104IAR in knee OA

Lake Street Captial Markets names Alex Nowak as director investment banking

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

Turnstone restructures to focus resources on advancing Phase 1 study

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Eupraxia expands Amanda Malone’s leadership role and names Rahul Sarugaser as EVP, corporate development

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

Valerio acquires oncology biotech, Emglev

General

More